ClinicalTrials.gg
RecruitingNCT06412562Updated May 14, 2024

M3VAS Validation in Polish Population

An observational study in Depressive Disorder, sponsored by Medical University of Gdansk. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Medical University of Gdansk · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Depressive Disorder with a site in Poland — 7 open to participants now, 7 under way, 2 of them phase 3. Depressive Disorder · Poland.

Started
2024
with 2 others
Observational
Only one
of the 21
Registered
17th of 21
by date
Lead sponsor
1 of 21
Medical University of Gdansk

Among the 21 studies in Depressive Disorder with a site in Poland, this one is one of 3 that started in 2024, is the only observational one, and was the 17th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

7 of the 21 studies in Depressive Disorder with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Depressive Disorder with a site in Poland, or all of them as a file.
02

Study summary

Low mood and anhedonia represent the fundamental symptoms of major depressive disorder (MDD). Nevertheless, there is currently no standardized visual analogue scale available to assess the extent of both symptoms concurrently. The Maudsley 3-item Visual Analogue Scale (M3VAS) is a newly developed tool for participants to self-assess core symptoms of depression: mood quality, pleasure experience (anhedonia), and suicidality. Despite suicidality not being a primary symptom, it is included due to its critical relevance to safety. Participants will be instructed to rate the intensity and frequency of their experiences over the preceding two weeks by marking a 100 mm ungraded line. A researcher will then assign a numerical value based on the mark's position, utilizing the left edge as 0 and the right as 100. The total score range, combining the three symptoms, ranged from 0 (minimum) to 300 (maximum). The M3VAS exhibited good psychometric properties in British population. In this study, the objective is to assess the psychometric properties of the scale within the Polish population diagnosed with major depressive episode within major depressive disorder or bipolar disorder.

03

Conditions studied

  • Depressive Disorder

Keywords

  • anhedonia; low mood; suicidality; depression; m3vas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Inpatients referred to the tertiary-reference unit for mood disorders with MDD or BD diagnosis, currently either with current depression or euthymic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis as provided by criteria:

Major depressive disorder (MDD) Bipolar disorder (BD)

Exclusion criteria

Exclusion Criteria:

Diagnosis as provided by criteria:

Psychotic disorders Current Mania or hypomania within bipolar disorder (BD)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Major Depressive Episode

    Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Major Depressive Disorder (MDD) or Bipolar Disorder (BD), as determined by a psychiatrist.

    Diagnostic Test: The Maudsley 3-item Visual Analogue Scale (M3VAS)

Interventions

  • Diagnostic testThe Maudsley 3-item Visual Analogue Scale (M3VAS)

    Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).

    Also known as: 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16)

06

What researchers measure

Primary outcomes

  1. The Maudsley 3-item Visual Analogue Scale (M3VAS)

    To analyze internal consistency and factor analysis

    Time frame: Baseline

Secondary outcomes

  1. 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16)

    To analyze convergent validity with The Maudsley 3-item Visual Analogue Scale (M3VAS)

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Medical University of Gdańsk
    Gdańsk, Poland
    Recruiting
    • Alina Wilkowska, MD, PhD · Contactalina.wilkowska@gumed.edu.pl · +48 58 584 46 50
    • Aleksander Kwaśny, MD · Contact+48 58 584 46 50
    • Alina Wilkowska, MD, PhD · Principal investigator
    • Aleksander Kwaśny, MD · Sub investigator
08

References and documents

Publications

  • Moulton CD, Strawbridge R, Tsapekos D, Oprea E, Carter B, Hayes C, Cleare AJ, Marwood L, Mantingh T, Young AH. The Maudsley 3-item Visual Analogue Scale (M3VAS): Validation of a scale measuring core symptoms of depression. J Affect Disord. 2021 Mar 1;282:280-283. doi: 10.1016/j.jad.2020.12.185. Epub 2020 Dec 31. PubMed 33418379 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Sep 2026, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
May 9, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06412562
Responsible party
Sponsor
First posted
May 14, 2024
Start date
May 9, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
May 14, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion